Literature DB >> 12400847

Aluminum deposition in the bone of patients with chronic renal failure--detection of aluminum accumulation without signs of aluminum toxicity in bone using acid solochrome azurine.

M Rüster1, K Abendroth, G Lehmann, G Stein.   

Abstract

In this study, the sensitivity of the aurine tricarboxylic acid (ATA) and acid solochrome azurine (ASA) stain for aluminum were compared under special consideration of the relationship to bone histology in renal osteodystrophy. Al deposition in iliac crest bone biopsies taken from 78 patients with chronic renal failure (CRF) was assessed histochemically using the ATA and ASA stain; the Al accumulation was correlated with bone histology and histomorphometry. Significantly more Al was detectable with the ASA method on trabecular bone surfaces and cement lines (18 +/- 20% vs 4 +/- 12% on surfaces; 13 +/- 18% vs 0.4 +/- 1.3% on cement lines). In 31 cases in which ATA yielded negative results, ASA in contrast indicated Al deposits on up to 20% of the trabecular bone surface. The specimens with more Al on the trabecular bone surface had a significantly higher osteoid volume and osteoid surface. With ATA, these differences were observed at a staining of > or = 10% of the trabecular surface, with ASA at a staining of > or = 40% of the trabecular surface. Therefore, it seems to be possible to detect a very low Al deposition, without any Al-induced changes in bone morphology or signs of Al toxicity in the bone using the ASA method. By contrast, a positive ATA stain is mainly found in biopsies with typical signs of Al-induced changes of histomorphometric bone parameters. We, therefore, recommend the routine use of the ASA stain to detect Al deposition in bone.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12400847     DOI: 10.5414/cnp58305

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  3 in total

Review 1.  Human health risk assessment for aluminium, aluminium oxide, and aluminium hydroxide.

Authors:  Daniel Krewski; Robert A Yokel; Evert Nieboer; David Borchelt; Joshua Cohen; Jean Harry; Sam Kacew; Joan Lindsay; Amal M Mahfouz; Virginie Rondeau
Journal:  J Toxicol Environ Health B Crit Rev       Date:  2007       Impact factor: 6.393

Review 2.  Pharmacology, efficacy and safety of oral phosphate binders.

Authors:  Alastair J Hutchison; Craig P Smith; Paul E C Brenchley
Journal:  Nat Rev Nephrol       Date:  2011-09-06       Impact factor: 28.314

3.  Metal deposition in calcific uremic arteriolopathy.

Authors:  Lavanya Amuluru; Whitney High; Kim M Hiatt; James Ranville; Sudhir V Shah; Bilal Malik; Sundararaman Swaminathan
Journal:  J Am Acad Dermatol       Date:  2009-04-29       Impact factor: 11.527

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.